Cargando…

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis

INTRODUCTION: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab clinical trials. METHODS: Animated visualizations...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkes, Jason E., See, Kyoungah, Burge, Russel, Strakbein, Stephanie, McKean-Matthews, Missy, Saure, Daniel, Gooderham, Melinda, Leonardi, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322243/
https://www.ncbi.nlm.nih.gov/pubmed/34050899
http://dx.doi.org/10.1007/s13555-021-00548-2
_version_ 1783731010833219584
author Hawkes, Jason E.
See, Kyoungah
Burge, Russel
Strakbein, Stephanie
McKean-Matthews, Missy
Saure, Daniel
Gooderham, Melinda
Leonardi, Craig
author_facet Hawkes, Jason E.
See, Kyoungah
Burge, Russel
Strakbein, Stephanie
McKean-Matthews, Missy
Saure, Daniel
Gooderham, Melinda
Leonardi, Craig
author_sort Hawkes, Jason E.
collection PubMed
description INTRODUCTION: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab clinical trials. METHODS: Animated visualizations were developed to show outcomes from ixekizumab clinical trials and a Bayesian network meta-analysis of 11 approved biologics. The visualizations simultaneously highlighted both aggregate scores and the individual progression of patients over the course of treatment. RESULTS: The animations provided key messages and information from the complex data in efficient and scientific ways that were also visually pleasing and simple to understand. The animations highlighted (1) rapid reduction in disease severity from baseline; (2) sustained efficacy of ixekizumab in the treatment of skin and nail psoriasis; (3) side-by-side comparisons of treatment efficacy and clinical improvement across trials; (4) simultaneous visual presentation of individual results with summary response over time; and (5) indirect comparison of relative treatment effects with other biologics based on Bayesian network meta-analysis. CONCLUSION: The rapid and sustained efficacy of ixekizumab in the treatment of psoriasis was demonstrated using multiple dynamic visualizations with different clinical endpoints. Animated visualizations provided a simpler and more comprehensive understanding of complex data than conventional static figures. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-021-00548-2.
format Online
Article
Text
id pubmed-8322243
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-83222432021-08-19 Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis Hawkes, Jason E. See, Kyoungah Burge, Russel Strakbein, Stephanie McKean-Matthews, Missy Saure, Daniel Gooderham, Melinda Leonardi, Craig Dermatol Ther (Heidelb) Review INTRODUCTION: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab clinical trials. METHODS: Animated visualizations were developed to show outcomes from ixekizumab clinical trials and a Bayesian network meta-analysis of 11 approved biologics. The visualizations simultaneously highlighted both aggregate scores and the individual progression of patients over the course of treatment. RESULTS: The animations provided key messages and information from the complex data in efficient and scientific ways that were also visually pleasing and simple to understand. The animations highlighted (1) rapid reduction in disease severity from baseline; (2) sustained efficacy of ixekizumab in the treatment of skin and nail psoriasis; (3) side-by-side comparisons of treatment efficacy and clinical improvement across trials; (4) simultaneous visual presentation of individual results with summary response over time; and (5) indirect comparison of relative treatment effects with other biologics based on Bayesian network meta-analysis. CONCLUSION: The rapid and sustained efficacy of ixekizumab in the treatment of psoriasis was demonstrated using multiple dynamic visualizations with different clinical endpoints. Animated visualizations provided a simpler and more comprehensive understanding of complex data than conventional static figures. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-021-00548-2. Springer Healthcare 2021-05-29 /pmc/articles/PMC8322243/ /pubmed/34050899 http://dx.doi.org/10.1007/s13555-021-00548-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Hawkes, Jason E.
See, Kyoungah
Burge, Russel
Strakbein, Stephanie
McKean-Matthews, Missy
Saure, Daniel
Gooderham, Melinda
Leonardi, Craig
Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
title Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
title_full Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
title_fullStr Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
title_full_unstemmed Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
title_short Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
title_sort dynamic visual representation of clinical efficacy of ixekizumab in psoriasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322243/
https://www.ncbi.nlm.nih.gov/pubmed/34050899
http://dx.doi.org/10.1007/s13555-021-00548-2
work_keys_str_mv AT hawkesjasone dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis
AT seekyoungah dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis
AT burgerussel dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis
AT strakbeinstephanie dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis
AT mckeanmatthewsmissy dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis
AT sauredaniel dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis
AT gooderhammelinda dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis
AT leonardicraig dynamicvisualrepresentationofclinicalefficacyofixekizumabinpsoriasis